Novartis to acquire Avidity Biosciences for $12 billion

Novartis AG announced its intent to acquire Avidity Biosciences for $12 billion in cash, offering $72.00 per share, a 46% premium, to significantly enhance its neuroscience franchise. The acquisition will integrate Avidity's late-stage programs for genetic neuromuscular diseases and its Antibody Oligonucleotide Conjugates (AOCs) platform, with Novartis projecting an increase in its 2024-2029 sales compound annual growth rate from 5% to 6%. The deal, which requires regulatory and Avidity stockholder approval and includes a spin-off of Avidity's early-stage cardiology programs, is expected to close in the first half of 2026.

Analysis

Novartis AG has announced a definitive agreement to acquire Avidity Biosciences for $12 billion in cash, offering $72.00 per share, which represents a significant 46% premium to Avidity's closing price on October 24. This valuation is notable given Avidity's current market capitalization of $7.06 billion and its negative EPS of -$3.57 over the last twelve months, indicating Novartis's strong confidence in the acquired technology and pipeline. The transaction, subject to regulatory and stockholder approvals, is anticipated to close in the first half of 2026, with Avidity's early-stage cardiology programs being spun off to existing shareholders.

The acquisition is strategically aimed at bolstering Novartis's neuroscience franchise by integrating Avidity's Antibody Oligonucleotide Conjugates (AOCs) platform and three late-stage programs targeting genetic neuromuscular diseases. Novartis projects this deal will enhance its 2024-2029 sales compound annual growth rate from 5% to 6% and reinforce its mid-single digit long-term growth trajectory. Product launches from the acquired pipeline are expected before 2030, aligning with Novartis's commitment to innovative, targeted medicines.

Despite Avidity's current unprofitability, the substantial acquisition premium and recent analyst actions reflect a positive market outlook for its platform. H.C. Wainwright raised its price target to $87, and BofA Securities to $65, both maintaining Buy ratings, following positive data from Duchenne muscular dystrophy studies. Avidity also successfully raised $690 million through a public offering, demonstrating investor confidence prior to the acquisition announcement.

Key Decisions for Investors

• Investors holding RNA should evaluate the $72.00 per share cash offer against the 46% premium and the value of the SpinCo shares they will receive, considering the H1 2026 closing timeline and potential regulatory hurdles.
• NVS investors should monitor the integration of Avidity's AOC platform and late-stage pipeline, assessing the execution risk against the projected increase in sales CAGR from 5% to 6%.
• Given the extended closing period, investors may consider arbitrage strategies or re-evaluating their positions based on deal certainty and the potential for competing bids.